The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

Renal hypoperfusion occurs as a result of reduced cardiac output, resulting in the activation of the renin–angiotensin–aldosterone system, which compensates for the hypoperfusion. However ...

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone.

chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the fourth quarter and full year ending ...

S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –– ...

Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 25 percent of all hypertensive patients. CKD, which is characterized by the gradual loss of kidney function, ...